Table IV.
Gene/protein | Source tissue | Method | Increase in HFD versus CD (p < 0.05) | No statistically significant difference between HFD and CD | Decrease in HFD versus CD (p < 0.05) |
---|---|---|---|---|---|
Proinflammatory cytokines | |||||
IL-1α | Serum | ELISA | N/A | 2 studies33,34 | N/A |
IL-1β | Knee joint | GE | 2 studies27,29 | N/A | N/A |
IL-1β | Serum | ELISA | N/A | 2 studies12,33 | N/A |
IL-6 | Knee joint;5 visceral adipose6 | GE | 1 study5 | 1 study6 | N/A |
IL-6 | Serum | ELISA | 1 study12 | N/A | N/A |
IL-8 or KC | Serum | ELISA | N/A | 1 study12 | N/A |
IL-13 | Knee joint | GE | 1 study27 | N/A | N/A |
IFNγ | Serum | ELISA | N/A | 3 studies12,33,34 | N/A |
TNF-α | Knee joint | GE | 3 studies5,27,31 | 1 study6 | N/A |
TNF-α | Serum | ELISA | Excluded | N/A | N/A |
NLRP3 | Knee joint | GE | 1 study29 | N/A | N/A |
CCL2 or MCP-1 | Knee joint;27 visceral adipose6 | GE | 1 study27 | 1 study6 | N/A |
CCL3 or MIP1α | Knee joint | GE | 1 study27 | 1 study34 | N/A |
CCL7 or MCP-3 | Knee joint | GE | 1 study27 | N/A | N/A |
CD11c | Visceral adipose | GE | N/A | 1 study6 | N/A |
Casp1 | Knee joint | GE | 1 study27 | N/A | N/A |
CCR1 or CD191 | Knee joint | GE | N/A | 1 study27 | N/A |
CCR3 | Knee joint | GE | N/A | 1 study27 | N/A |
CCR5 | Knee joint | GE | N/A | 1 study27 | N/A |
MIG or CXCL9 | Serum | ELISA | 1 study33 | N/A | N/A |
IL-12 | Serum | ELISA | N/A | 1 study34 | N/A |
IL-12p70 | Serum | ELISA | 1 study12 | N/A | N/A |
F4/80 | Visceral adipose | GE | N/A | 1 study6 | N/A |
Anti-inflammatory cytokines | |||||
IL-4 | Knee joint | GE | N/A | 1 study27 | N/A |
IL-4 | Serum | ELISA | N/A | N/A | 1 study33 |
IL-10 | Knee joint | GE | N/A | 1 study27 | N/A |
IL-10 or CXCL10 | Serum | ELISA | N/A | 2 studies12,33 | N/A |
IL-1Ra | Serum | ELISA | 1 study33 | 1 study33 | N/A |
Proteins directly involved with cartilage metabolism | |||||
TGF-β1 | Knee joint | GE | 1 study5 | N/A | N/A |
TGF-β1 | Serum | ELISA | N/A | 1 study6 | N/A |
VEGF-a | Knee joint | GE | 2 studies5,31 | N/A | N/A |
ColX | Knee articular cartilage | IHC | N/A | 1 study30 | N/A |
SOX9 | Knee articular cartilage | IHC | N/A | 1 study30 | N/A |
MMP13 | Knee articular cartilage | IHC | 1 study29 | N/A | N/A |
MMP13 | Knee articular cartilage | IHC | N/A | 1 study30 | N/A |
MMP3 | Knee joint | GE | 1 study27 | N/A | N/A |
TIMP-3 | Knee joint | GE | 1 study27 | N/A | N/A |
TIMP-3 | Knee articular cartilage | IHC | N/A | 1 study30 | N/A |
Lipocalin2 | Knee joint | GE | 1 study31 | N/A | N/A |
Nampt | Knee joint | GE | 2 studies5,31 | N/A | N/A |
PGE2 | Serum | ELISA | N/A | N/A | N/A |
p-PKCδ | Knee articular cartilage | IHC | N/A | 1 study30 | N/A |
p-ERK1/2 | Knee articular cartilage | IHC | N/A | 1 study30 | N/A |
RUNX2 | Knee articular cartilage | IHC | N/A | 1 study30 | N/A |
bFGF | Serum | ELISA | N/A | 1 study33 | N/A |
ADAMTS5 | Knee articular cartilage | IHC | N/A | 1 study30 | N/A |
iNOS | Knee joint | GE | 1 study29 | N/A | N/A |
p-NF-κB | Knee articular cartilage | IHC | N/A | 1 study30 | N/A |
Adipokines involved in obesity and inflammatory processes | |||||
Leptin | Knee joint | GE | 2 studies5,31 | N/A | N/A |
Leptin | Serum | ELISA | 3 studies4,6,33 | 1 study34 | N/A |
Adiponectin | Knee joint | GE | N/A | 1 study12 | N/A |
Adiponectin | Serum | ELISA | 1 study33 | N/A | 1 study12 |
Resistin | Serum | ELISA | N/A | Undetected12 | N/A |
Chemerin | Knee joint | GE | 1 study31 | N/A | N/A |
Insulin | Serum | ELISA | 2 studies4,6 | N/A | N/A |
OA, osteoarthritis; HFD, high-fat diet; CD, control diet; IL, interleukin; ELISA, enzyme-linked immunosorbent assay; N/A, not applicable; GE, gene expression; KC, keratinocyte-derived chemokine; IFNγ, interferon gamma; TNF, tumor necrosis factor; NRLP3, NOD-like receptor family pyrin domain-containing 3; CCL, chemokine ligand; MCP, monocyte-chemotactic protein; MIP, macrophage inflammatory protein; CD11c, integrin alpha X; Casp1, caspase-1; CCR, C-C chemokine receptor; MIG, monokine induced by gamma; CXCL, chemokine (C-X-C motif) ligand; F4/80, adhesion G protein-coupled receptor E1; IL-1RA, interleukin-1 receptor antagonist; TGF-β1, transforming growth factor beta 1; VEGF-a, vascular endothelial growth factor-a; IHC, immunohistochemistry; ColX, collagen X; SOX9, SRY-Box Transcription Factor 9; MMP, matrix metallopeptidase; TIMP-3, TIMP metallopeptidase inhibitor 3; Nampt, nicotinamide phosphoribosyltransferase; PGE2, prostaglandin E2; p-PKCδ, phospho-protein kinase C delta; p-ERK1/2, phospho-extracellular signal-regulated protein kinases 1 and 2; RUNX2, Runt-related transcription factor 2; bFGF, basic fibroblast growth factor; ADAMTS5, a disintegrin-like and metalloproteinase with thrombospondin-1 motifs, member 5; iNOS, inducible nitric oxide synthase; p-NF-κB; phospho-nuclear factor kappa-light-chain-enhancer of activated B cells